Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04324840 · ClinicalTrials.gov registry record · Phase 1
A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma
A Phase 1 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 184
- Enrollment target
NCT04324840 is a Phase 1 study that was terminated before completion, run by Celgene. The registered enrollment target is 184 participants.
The verdict
NCT04324840, a Phase 1 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 184 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of CC-90010 when combined with standard of care treatment, temozolomide (TMZ) with or without radiotherapy (RT) in the newly diagnosed WHO Grade IV glioblastoma (ndGBM).
Interventions
- DRUG Temozolomide
- RADIATION Radiotherapy
- DRUG CC-90010
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2020-07-10 |
| Est. Completion | 2024-07-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04324840
The ClinicalTrials.gov registry entry for NCT04324840 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Temozolomide is the first listed.
NCT04324840 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04324840 about?
NCT04324840 is a clinical study titled "A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma". The purpose of this study is to determine the safety and tolerability of CC-90010 when combined with standard of care treatment, temozolomide (TMZ) with or without radiotherapy (RT) in the newly diagnosed WHO Grade IV glioblastoma (ndGBM).
What is the current status of trial NCT04324840?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 184 participants. The study started on 2020-07-10. Estimated completion is 2024-07-09.
What interventions are being tested in trial NCT04324840?
The interventions under investigation include: Temozolomide (DRUG), Radiotherapy (RADIATION), CC-90010 (DRUG).
Who is sponsoring clinical trial NCT04324840?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.